ArticleBMJ open2026
Novel triglyceride-lowering therapies to reduce the risk of acute pancreatitis in hypertriglyceridaemia: a protocol for systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypertriglyceridaemia is a major risk factor and rising aetiology for acute pancreatitis (AP), a condition associated with significant morbidity and mortality. Novel triglyceride-lowering therapies targeting key regulators of lipoprotein metabolism, specifically apolipoprotein C-III (APOC3), angiopoietin-like 3 protein (ANGPTL3) and angiopoietin-like 4 protein (ANGPTL4), have shown promise in reducing triglyceride levels. This study aims to evaluate the efficacy and safety of APOC3, ANGPTL3 and ANGPTL4 inhibitors for reducing the episodes of AP in patients with hypertriglyceridaemia. METHODS AND ANALYSIS: A systematic search of PubMed (National Library of Medicine), Web of Science (Clarivate), Embase (Ovid) and the Cochrane Library (Wiley) will be conducted to identify randomised controlled trials published from inception to May 2026. Eligible studies will include adults with hypertriglyceridaemia (fasting triglyceride level ≥500 mg/dL (5.6 mmol/L)), comparing APOC3, ANGPTL3 or ANGPTL4 inhibitors against placebo. The primary outcome will be the incidence of AP. Secondary outcomes include the per cent change in lipid parameters (triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol) and safety profiles. Two reviewers will independently conduct study selection, data extraction and risk of bias assessment. Meta-analysis will be performed using R software, with effects expressed as risk ratio for dichotomous outcomes and mean differences for continuous outcomes. Heterogeneity, subgroup analyses, sensitivity analyses and publication bias will be assessed. The certainty of evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework. ETHICS AND DISSEMINATION: Ethical review is not required as this study involves no human participants and relies on previously published data. The findings will be disseminated through peer-reviewed journals. PROSPERO REGISTRATION NUMBER: CRD420251174198.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.